1. Home
  2. NTLA vs EYE Comparison

NTLA vs EYE Comparison

Compare NTLA & EYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

SELL

Current Price

$11.36

Market Cap

1.6B

Sector

Health Care

ML Signal

SELL

Logo National Vision Holdings Inc.

EYE

National Vision Holdings Inc.

HOLD

Current Price

$17.89

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTLA
EYE
Founded
2014
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Ophthalmic Goods
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.4B
IPO Year
2016
2017

Fundamental Metrics

Financial Performance
Metric
NTLA
EYE
Price
$11.36
$17.89
Analyst Decision
Buy
Buy
Analyst Count
20
11
Target Price
$23.11
★ $27.50
AVG Volume (30 Days)
★ 4.9M
1.8M
Earning Date
11-17-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
27.43
★ 202.78
EPS
N/A
★ 0.54
Revenue
$67,671,000.00
★ $1,987,488,000.00
Revenue This Year
N/A
$3.56
Revenue Next Year
$143.36
$5.05
P/E Ratio
★ N/A
$33.22
Revenue Growth
★ 16.92
9.00
52 Week Low
$7.95
$14.75
52 Week High
$18.48
$30.02

Technical Indicators

Market Signals
Indicator
NTLA
EYE
Relative Strength Index (RSI) 52.25 55.78
Support Level $11.26 $15.37
Resistance Level $13.50 $19.03
Average True Range (ATR) 0.81 0.88
MACD 0.05 0.00
Stochastic Oscillator 51.49 76.46

Price Performance

Historical Comparison
NTLA
EYE

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

About EYE National Vision Holdings Inc.

National Vision Holdings Inc. is an optical retailer in the United States. Its product portfolio includes eyeglasses, sunglasses, contact lenses, accessories, and other related products. The company operates through a single operating segment. The Owned and Host segment includes the company-owned brands America's Best and Eyeglass World. In America's Best stores, vision care services are provided by optometrists or by independent professional corporations. The Host segment consists of Military and Fred Meyer locations, where eye exams are provided by independent optometrists.

Share on Social Networks: